Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic in Liver Transplant Recipients
NCT00167492Phase 4Withdrawn
- Sponsor
- UTHealth Houston
- Start
- Sep 2005
- Primary completion
- Feb 2009
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in liver transplantation, sponsored by UTHealth Houston. Primary endpoints: Rate of rejection at 6 months and Rate of gastrointestinal side-effects at 6 months. Planned start Sep 2005; status: withdrawn.
02
Drugs
mycophenolate sodium
03
Conditions
liver transplantation
Beyond the preview
Go deeper on NCT00167492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167492.